Study of MGC028 for Advanced Solid Tumors
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests a new drug called MGC028 for people with certain advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of cancer that has spread and cannot be removed by surgery, and it must be one of: non-small cell lung cancer (adenocarcinoma), bile duct cancer, colorectal cancer, or pancreatic cancer.
- Standard treatments must have stopped working, or you must not be able to take them because of side effects, or they are not available for your cancer.
- You need to have a tumor that can be measured on a scan (like a CT scan).
- Your medical team will need to have a sample of your tumor tissue (either from a past biopsy or you agree to a new one).
- You must be healthy enough to take part in the study, as determined by your doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, MRG006A, for people with advanced solid tumors, especially liver cancer. It aims to see if the drug is safe and effective by targeting a protein called GPC3 found on some cancer cells.
This trial tests an experimental drug for people with advanced solid tumors or lymphoma that has not responded to standard treatments and has a specific genetic change (loss of MTAP or CDKN2A genes). The drug is taken by mouth and may work by targeting cancer cells with this change.
This trial tests a new drug, CM518D1, for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective, and may offer a new option for those who have few choices left.
This trial tests a new drug that targets a protein called MET found on some cancer cells. It may help people with certain advanced cancers that have not responded to other treatments.
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
This trial tests a new investigational drug called MGC030 for people with advanced solid tumors, including bladder, colorectal, stomach, esophageal, or pancreatic cancer. The goal is to see if the drug is safe and can help shrink or control the cancer when standard treatments have stopped working.
Hear when a new NSCLC Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.